Medline Inc. faces pressure from private equity overhang and a recent downward revision in FY26 adj. EBITDA guidance. I rate the MDLN stock a hold. Read my full analysis.
US housing and commercial real estate are under stress as sales slump, rates stay high, and office delinquencies rise. Read what investors need to know.
Shares of complement system biotech Omeros Corporation (OMER) have rallied 406% in the past 11 months, triggered by an out-licensing deal with Novo Nordisk...
ADSs of cancer therapy concern Adlai Nortye Group (ANL) have rallied 1,606% since early December 2025, largely on confidence inspired by two private...
Shares of Covid-19 vaccine and oncology concern BioNTech SE (BNTX) have remained primarily in a range of $80 to $120 over the past 40 months as the market...